Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report

Figure 2 Pathological images of the surgical specimens. A and B: Pulmonary sarcomatoid carcinoma was diagnosed (A: hematoxylin and eosin [H&E] staining, 100 ×; B: H&E staining, 200 ×); C and D: Adenocarcinoma also present (C: H&E staining, 100 ×; D: H&E staining, 200 ×); E and F: Immunohistochemical staining showed that the tumor cells were positive for programmed death-ligand 1 expression, tumor proportion score: 90% (E: pulmonary sarcomatoid carcinoma, immunohistochemical staining, 200 ×; F: adenocarcinoma, immunohistochemical staining, 200 ×).